Key result
Sacubitril/valsartan therapy significantly increased global constructive work from 720.2 to 900.6 mmHg% (P=0.016) and improved global work efficiency at 6 months in heart failure patients.
Why the study?
Myocardial work is a new echocardiographic parameter that enhances information from LV GLS, but the impact of sacubitril/valsartan therapy on myocardial work parameters is unknown.
Does sacubitril/valsartan improve left ventricular myocardial work parameters in patients with chronic heart failure and reduced ejection fraction?
Population
42 chronic heart failure patients with LV ejection fraction of 40% or less despite optimized standard therapy
Comparison
Before vs 6 months after starting sacubitril/valsartan (LCZ696) therapy
Design
Prospective cohort study
Follow-up
6 months
Authors
Loading...
May improve myocardial work indices in HF; hypothesis-generating and requires RCT confirmation before practice change.
Observational (n=42)
Does sacubitril/valsartan improve left ventricular myocardial work parameters in patients with chronic heart failure and reduced ejection fraction?
Absolute Event Rate: 900.6% vs 720.2%
p-value: p=0.016
Sacubitril/valsartan therapy is associated with significant improvements in novel echocardiographic parameters of myocardial work and reverse remodeling at 6 months in patients with HFrEF.
Gonçalves et al. (2020) conducted an observational in chronic heart failure (n=42). sacubitril/valsartan (LCZ696) vs. baseline was evaluated on global constructive work (p=0.016). Sacubitril/valsartan therapy significantly increased global constructive work from 720.2 to 900.6 mmHg% (P=0.016) and improved global work efficiency at 6 months in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: